FUJIFILM Cellular Dynamics, Inc., a leading global developer and
manufacturer of human induced pluripotent stem cells (iPSC)
technologies, and Sana Biotechnology, Inc. (NASDAQ: SANA), a
company focused on creating and delivering engineered cells as
medicines, announced today that Sana has been granted a
non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC
platform for the development of commercial cell therapies. As a
treatment modality, cell therapies have the potential to augment,
repair, or replace human biology, including organs, tissues and
cells.
Under the agreement, FUJIFILM Cellular Dynamics
grants Sana a non-exclusive license under intellectual property
rights owned or controlled by FUJIFILM Cellular Dynamics, and will
provide iPSC cell lines (including research-grade and/or Good
Manufacturing Practices (GMP)-grade iPSC lines) to Sana. Sana may
use the iPSC cell lines, and exercise the licensed intellectual
property rights, for the research and development, and with respect
to GMP-grade cell lines, clinical and commercial manufacture, and
commercialization, of cell therapies derived from such lines. Terms
of the agreement were not disclosed.
“FUJIFILM Cellular Dynamics is a leading global
player in the field of iPSCs. Our history in manufacturing iPSCs
for research-purposes has provided us with the foundational
expertise to manufacture quality GMP-grade iPSC lines,” said
Takeshi Yamamoto, chief executive officer, FUJIFILM Cellular
Dynamics. “Sana is developing a broad and compelling pipeline of
iPSC-derived cellular therapies, and we are pleased to grant them
the rights to our iPSC platform with a vision of providing more
treatment options for patients.”
“Sana is committed to the development of engineered
cells as medicines that can be manufactured at scale and supplied
to patients globally,” said Stacey Ma, executive vice president,
technical operations, Sana. “FUJIFILM Cellular Dynamics is a
long-standing innovative leader in this field, and we are thrilled
to have the opportunity to combine their expertise in GMP-grade
iPSC cell lines with our investment in differentiating and
manufacturing cells at scale for patients across a number of
diseases.”
About FUJIFILMFUJIFILM Cellular
Dynamics, Inc. is a leading developer and manufacturer of human
induced pluripotent stem cells (iPSCs) utilized in drug discovery,
contract development and manufacturing services, and cell
therapies. FUJIFILM Cellular Dynamics is using its expertise in
iPSC technologies to develop robust cell therapeutics products to
address unmet medical needs in areas such as age-related macular
degeneration, retinitis pigmentosa and autoimmune diseases. For its
partners, FUJIFILM Cellular Dynamics utilizes its iPSC platform to
advance the progress of therapeutic candidates in the clinic and
provides contract development and manufacturing (CDMO) services. In
addition to cell therapy, FUJIFILM Cellular Dynamics also offers
life science research tools including the company’s inventoried
iCell® products, which are available in almost any cell type and
are sourced from multiple cell lines which can be applied for
target identification as well as toxicity testing. The company also
offers custom cell services and cell banking. FUJIFILM Cellular
Dynamics’ goal is to leverage the vast utility of iPSCs to advance
human health and improve the quality of life for patients around
the world. For more information, please
visit: https://www.fujifilmcdi.com/
FUJIFILM Holdings Corporation, Tokyo, Japan,
brings cutting edge solutions to a broad range of global industries
by leveraging its depth of knowledge and fundamental technologies
developed in its relentless pursuit of innovation. Its proprietary
core technologies contribute to the various fields including
healthcare, highly functional materials, document and imaging
products. These products and services are based on its extensive
portfolio of chemical, mechanical, optical, electronic and imaging
technologies. For the year ended March 31, 2020, the company had
global revenues of $21 billion, at an exchange rate of 109 yen to
the dollar. Fujifilm is committed to responsible environmental
stewardship and good corporate citizenship. For more information,
please visit: www.fujifilmholdings.com
About Sana BiotechnologySana
Biotechnology, Inc. is focused on creating and delivering
engineered cells as medicines for patients. We share a vision of
repairing and controlling genes, replacing missing or damaged
cells, and making our therapies broadly available to patients. We
are more than 250 people working together to create an enduring
company that changes how the world treats disease. Sana has
operations in Seattle, Cambridge, and South San Francisco. For more
information about Sana Biotechnology please visit
https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the potential for the Company to develop
treatment options for patients using rights from the FUJIFILM
Cellular Dynamics’ GMP-grade iPSC cell lines. All statements other
than statements of historical facts contained in this press
release, including, among others, statements regarding the
Company’s strategy, expectations, cash runway and future financial
condition, future operations, and prospects, are forward-looking
statements. In some cases, you can identify forward-looking
statements by terminology such as “aim,” “anticipate,” “assume,”
“believe,” “contemplate,” “continue,” “could,” “design,” “due,”
“estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“positioned,” “potential,” “predict,” “seek,” “should,” “target,”
“will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. The Company has based
these forward-looking statements largely on its current
expectations, estimates, forecasts and projections about future
events and financial trends that it believes may affect its
financial condition, results of operations, business strategy and
financial needs. In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These
statements are subject to risks and uncertainties that could cause
the actual results to vary materially, including, among others, the
risks inherent in drug development such as those associated with
the initiation, cost, timing, progress and results of the Company’s
current and future research and development programs, preclinical
and clinical trials. For a detailed discussion of the risk factors
that could affect the Company’s actual results, please refer to the
risk factors identified in the Company’s SEC reports, including but
not limited to its prospectus dated February 3, 2021. Except as
required by law, the Company undertakes no obligation to update
publicly any forward-looking statements for any reason.
All product and company names herein may be
trademarks of their registered owners.
FUJIFILM Contact:Christine
JackmanFujifilm(914) 789-8523christine.jackman@fujfilm.com
Sana Biotechnology
Contacts:Investor RelationsNicole
Keithinvestor.relations@sana.com
MediaMorgan Warners, Finsbury
Glover Heringmedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sana Biotechnology (NASDAQ:SANA)
Historical Stock Chart
From Jul 2023 to Jul 2024